Effects of Esketamine on the Incidence of Postoperative Delirium and Postoperative Sleep Disturbance in Elderly Patients After Major Non-cardiac Surgery
Key facts
- Who runs it
- RenJi Hospital
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Withdrawn
- Started
- 1 Apr 2025
- Ended
- 30 Sept 2026
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Esketamine
- 0.9 % saline
- Record updated
- 16 May 2025
- Why it stopped
- The trial protocol has undergone substantial revisions, including modifications to the primary outcome measure, which fundamentally alter the original study objectives. As these changes are not compatible with the initial registration, we
Who can take part
- Age
- 65 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (17)Hide the full registry criteria
Who can take part
- Age ≧ 65 years
- ASA Ⅰ-Ⅲ
- Elective major non-cardiac surgery
- Voluntary signed informed consent
Who cannot take part
- Emergency or trauma surgery
- Prior history of postoperative delirium or postoperative cognitive decline
- People with mental illness
- Suffering from serious central nervous system disorders such as arkinson's disease, Alzheimer's disease, etc
- Suffering from severe systemic underlying diseases (e.g. cardiac insufficiency, malignant arrhythmia, malignant hypertension, hepatic failure, renal failure, etc.)
- Patients with stage 3 or 4 malignant tumors, pancreatic cancer, allbladder cancer, cholangiocarcinoma and other tumors with high malignancy and poor prognosis
- history of allergy to or contraindication to esketamine
- Elevated intracranial pressure
- The patient has impaired hearing or impaired vision
- The patient is in chronic pain
- The patient is severely malnourished
- inability or unwillingness to complete questionnaires or clinical testing
- Unable or unwilling to use a postoperative intravenous analgesic pump
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Postoperative delirium (POD) is a common surgical complication.It is associated with a range of negative outcomes such as delayed postoperative recovery,prolonged hospitalization,additional medical expenditures and higher mortality.
Read full original descriptionShow less
Meanwhile,sleep disorders are not only an important predisposing factor for delirium,but also one of the main symptoms of delirium.Systemic inflammatory responses caused by sleep disorders may be an important mechanism for POD.
Many studies have shown that esketamie may inhibit inflammatory factors and enhance neuroplasticity.
In summary,we felt the need to further explore the therapeutic potential of esketamine in the area of POD as well as postoperative sleep disorders.
The 2 groups in the trial
- esketamine groupTreatment being tested
The esketamine group patients will be received esketamine perioperatively.
Treatment: Esketamine
- Placebo groupPlacebo, for comparison
The placebo group patients will be received 0.9% saline perioperatively.
Treatment: 0.9 % saline
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Effects of Esketamine on the Incidence of Postoperative Delirium and Postoperative Sleep Disturbance in Elderly Patients After Major Non-cardiac Surgery: A Multi-Center Randomized Controlled Trial
- Record updated
- 16 May 2025